We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for real-time alerts, custom portfolio, and market movers
| Name | Symbol | Market | Type |
|---|---|---|---|
| Merck KGaA (PK) | USOTC:MKKGY | OTCMarkets | Depository Receipt |
| Price Change | % Change | Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.02 | 0.06% | 33.31 | 32.87 | 34.09 | 33.64 | 33.29 | 33.4927 | 19,012 | 21:28:42 |
From Jun 2022 to Jun 2024
By Cecilia Butini
Merck KGaA on Thursday backed its medium-term targets at group level and for its business units, and said that it plans further in-licensing deals and acquisitions as of next year.
The German pharmaceuticals-and-chemicals company said it remains on track to reach its growth target of 25 billion euros ($24.71 billion) in sales by 2025. Sales growth is expected at an average of 6% a year, which equates to an increase of more than EUR1 billion annually, the company said.
Merck backed a mid-term forecast at both group and divisional levels and said it continues to expect sales growth to progress in its life science, healthcare and electronics business.
"As of 2023, the group will once again consider potential larger-scale acquisitions as an option," Merck said, adding that it plans both bolt-on acquisitions and in-licensing deals.
Write to Cecilia Butini at cecilia.butini@wsj.com
(END) Dow Jones Newswires
October 06, 2022 02:40 ET (06:40 GMT)
Copyright (c) 2022 Dow Jones & Company, Inc.
1 Year Merck KGaA (PK) Chart |
1 Month Merck KGaA (PK) Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
